What longevity clinics offer, and what backs it up

A longevity clinic sells a package: a long appointment, a wide panel of tests, a report describing how your body is aging, and a plan combining lifestyle changes, supplements and sometimes prescription drugs used off-label. Prices run into thousands, the clinics are multiplying, and until recently they were almost entirely private.

That last part is changing, and the change is documented. A 2024 paper in GeroScience describes the establishment of healthy longevity clinics inside publicly funded hospitals, written by clinicians involved in setting them up. It is a useful document precisely because it is sympathetic: it describes what the field thinks it is doing, in its own terms.

What the clinics do, according to the field

The GeroScience authors describe healthy longevity medicine as integrating geroscience and other disciplines into clinical settings, with the aim of optimising health across a lifespan. They note that consumer engagement has grown and that private clinics are currently meeting that demand.

The clinical content they describe has three parts. Multidisciplinary teams of physicians and allied health professionals. Diagnostics built from medical history, physical examination and a range of clinical tests intended to detect early signs of age-related functional decline. And interventions spanning lifestyle modification, supplements, repurposed drugs, and social and environmental changes.

The paper also states plainly what is not yet in place: collaboration with research institutions and industry is described as crucial for advancing the field and for creating standardised protocols. Standardised protocols are, by definition, protocols that do not yet exist.

That is the honest shape of the sector. It is not quackery with a stethoscope, and it is not established medicine. It is a clinical practice being assembled while patients are already paying for it.

The diagnostics are the weakest link

The tests are where the gap between what is sold and what is supported is widest, and it is the part the customer sees first.

A large share of these panels produce an estimate of biological age, usually from an epigenetic clock. The research on whether those numbers mean anything for one person has moved sharply in the last two years, and it has moved against the product.

A 2026 study in Aging Cell evaluated 18 methylation-based aging biomarkers. Most were technically reproducible on replicate assays, but their biological reliability — whether the same person gives the same answer across samples taken hours apart, before and after meals, under stress — was substantially lower, with most showing only low to moderate stability. The authors noted that technical reproducibility did not predict biological reliability, which means a laboratory can be confident about its instrument and still not be measuring the person consistently.

A 2025 review in Epigenomics went further, arguing that technical and biological properties of these algorithms prohibit their current use at the individual level and that they do not meet the standards applied to established clinical biomarkers.

Every number on these reports is a surrogate endpoint — a stand-in for the outcome the customer cares about, used because that outcome takes a lifetime to observe. None has been validated by the standard a regulator would apply. A report built on such numbers can be scientifically current and still not tell a patient anything actionable, and the two are easy to confuse when the document is long and expensively produced.

The prescribing is real, and so is the data gap

The other distinctive service is prescribing approved drugs for an unapproved purpose. Rapamycin, approved as sirolimus for suppressing the immune system after transplantation, is the best-known example.

The scale of this practice has been measured, at least once. A 2023 survey in GeroScience collected data from 333 adults with a history of off-label rapamycin use, alongside 172 who had never used it, and reported initial evidence that the drug can be used safely in adults of normal health status. That is a real finding and a narrow one: it is a survey of people who chose the drug, and it speaks to tolerability rather than to benefit.

On benefit, a 2025 review in the journal Aging examined the human evidence for low-dose rapamycin and related compounds in healthy adults and concluded that the data have yet to establish that any of them is a proven therapy that can delay aging in healthy older adults, with larger cohorts needed.

So the position is this: a drug with strong animal evidence, reasonable short-term human safety data, and no demonstrated benefit for the purpose it is being prescribed for. Whether that justifies prescribing is a judgement about risk that a doctor and patient can legitimately make together. It is not a scientific finding, and it should not be presented to a patient as one.

What to ask a clinic

Three questions separate a clinic that knows where the evidence stops from one that does not.

Which clock does the biological age test use, and is it a principal-component version? The distinction is not marketing — it is the difference between a measurement with several years of technical noise and one with about 1.5.

What will change in my treatment depending on the result? If no answer exists, the test is being sold for its own sake.

Which of the things you are recommending have been tested in a randomised trial, and what did the trial measure? A clinic willing to answer that honestly is a clinic worth the money. The answer for most of the list will be “not yet”, and that answer is the beginning of an informed decision rather than the end of one.